b'<?xml version="1.0" ?>\n<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">\n<PubmedArticleSet>\n<PubmedArticle>\n    <MedlineCitation Status="MEDLINE" Owner="NLM">\n        <PMID Version="1">28579016</PMID>\n        <DateCompleted>\n            <Year>2019</Year>\n            <Month>04</Month>\n            <Day>16</Day>\n        </DateCompleted>\n        <DateRevised>\n            <Year>2019</Year>\n            <Month>04</Month>\n            <Day>16</Day>\n        </DateRevised>\n        <Article PubModel="Print-Electronic">\n            <Journal>\n                <ISSN IssnType="Electronic">1578-1852</ISSN>\n                <JournalIssue CitedMedium="Internet">\n                    <Volume>36</Volume>\n                    <Issue>7</Issue>\n                    <PubDate>\n                        <MedlineDate>2018 Aug - Sep</MedlineDate>\n                    </PubDate>\n                </JournalIssue>\n                <Title>Enfermedades infecciosas y microbiologia clinica</Title>\n                <ISOAbbreviation>Enferm. Infecc. Microbiol. Clin.</ISOAbbreviation>\n            </Journal>\n            <ArticleTitle>Executive summary of the GESIDA/National AIDS Plan Consensus Document on Antiretroviral Therapy in Adults Infected by the Human Immunodeficiency Virus (Updated January 2017).</ArticleTitle>\n            <Pagination>\n                <MedlinePgn>435-445</MedlinePgn>\n            </Pagination>\n            <ELocationID EIdType="pii" ValidYN="Y">S0213-005X(17)30131-3</ELocationID>\n            <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.eimc.2017.04.001</ELocationID>\n            <Abstract>\n                <AbstractText>Antiretroviral therapy (ART) is recommended for all patients infected by HIV-1. The objective of ART is to achieve an undetectable plasma viral load (PVL). Initial ART should be based on a combination of 3 drugs, including 2 nucleoside reverse transcriptase inhibitors (tenofovir in either of its two formulations plus emtricitabine or abacavir plus lamivudine) and another drug from a different family. Four of the recommended regimens, all of which have an integrase inhibitor as the third drug (dolutegravir, elvitegravir boosted with cobicistat or raltegravir), are considered preferential, whereas a further 3 regimens (based on elvitegravir/cobicistat, rilpivirine, or darunavir boosted with cobicistat or ritonavir) are considered alternatives. We present the reasons and criteria for switching ART in patients with an undetectable PVL and in those who present virological failure, in which case salvage ART should include 3 (or at least 2) drugs that are fully active against HIV. We also update the criteria for ART in specific situations (acute infection, HIV-2 infection, pregnancy) and comorbidities (tuberculosis or other opportunistic infections, kidney disease, liver disease and cancer).</AbstractText>\n                <CopyrightInformation>Copyright \xc2\xa9 2017. Publicado por Elsevier Espa\xc3\xb1a, S.L.U.</CopyrightInformation>\n            </Abstract>\n            <AuthorList CompleteYN="Y">\n                <Author ValidYN="Y">\n                    <CollectiveName>AIDS Study Group (GESIDA) of the Spanish Society of Infectious Diseases and Clinical Microbiology and the National AIDS Plan</CollectiveName>\n                </Author>\n            </AuthorList>\n            <Language>eng</Language>\n            <Language>spa</Language>\n            <PublicationTypeList>\n                <PublicationType UI="D016446">Consensus Development Conference</PublicationType>\n                <PublicationType UI="D016428">Journal Article</PublicationType>\n                <PublicationType UI="D017065">Practice Guideline</PublicationType>\n            </PublicationTypeList>\n            <ArticleDate DateType="Electronic">\n                <Year>2017</Year>\n                <Month>06</Month>\n                <Day>01</Day>\n            </ArticleDate>\n        </Article>\n        <MedlineJournalInfo>\n            <Country>Spain</Country>\n            <MedlineTA>Enferm Infecc Microbiol Clin</MedlineTA>\n            <NlmUniqueID>9104081</NlmUniqueID>\n            <ISSNLinking>0213-005X</ISSNLinking>\n        </MedlineJournalInfo>\n        <ChemicalList>\n            <Chemical>\n                <RegistryNumber>0</RegistryNumber>\n                <NameOfSubstance UI="D019380">Anti-HIV Agents</NameOfSubstance>\n            </Chemical>\n        </ChemicalList>\n        <CitationSubset>IM</CitationSubset>\n        <MeshHeadingList>\n            <MeshHeading>\n                <DescriptorName UI="D017088" MajorTopicYN="N">AIDS-Related Opportunistic Infections</DescriptorName>\n                <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D019380" MajorTopicYN="N">Anti-HIV Agents</DescriptorName>\n                <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>\n                <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>\n                <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D023241" MajorTopicYN="N">Antiretroviral Therapy, Highly Active</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D018791" MajorTopicYN="N">CD4 Lymphocyte Count</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D015897" MajorTopicYN="N">Comorbidity</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D016903" MajorTopicYN="N">Drug Monitoring</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D024882" MajorTopicYN="N">Drug Resistance, Viral</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D057915" MajorTopicYN="N">Drug Substitution</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D004359" MajorTopicYN="N">Drug Therapy, Combination</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D015658" MajorTopicYN="N">HIV Infections</DescriptorName>\n                <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D015497" MajorTopicYN="N">HIV-1</DescriptorName>\n                <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D015498" MajorTopicYN="N">HIV-2</DescriptorName>\n                <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D011247" MajorTopicYN="N">Pregnancy</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D011251" MajorTopicYN="N">Pregnancy Complications, Infectious</DescriptorName>\n                <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D019562" MajorTopicYN="N">Viral Load</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D014766" MajorTopicYN="N">Viremia</DescriptorName>\n                <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>\n            </MeshHeading>\n        </MeshHeadingList>\n        <KeywordList Owner="NOTNLM">\n            <Keyword MajorTopicYN="Y">AIDS</Keyword>\n            <Keyword MajorTopicYN="Y">Antiretroviral therapy</Keyword>\n            <Keyword MajorTopicYN="Y">Consensus document</Keyword>\n            <Keyword MajorTopicYN="Y">Documento de consenso</Keyword>\n            <Keyword MajorTopicYN="Y">GESIDA</Keyword>\n            <Keyword MajorTopicYN="Y">HIV infection</Keyword>\n            <Keyword MajorTopicYN="Y">Infecci\xc3\xb3n por VIH</Keyword>\n            <Keyword MajorTopicYN="Y">Plan Nacional sobre el Sida</Keyword>\n            <Keyword MajorTopicYN="Y">Recomendaciones</Keyword>\n            <Keyword MajorTopicYN="Y">Recommendations</Keyword>\n            <Keyword MajorTopicYN="Y">Sida</Keyword>\n            <Keyword MajorTopicYN="Y">Spanish National AIDS Plan</Keyword>\n            <Keyword MajorTopicYN="Y">Tratamiento antirretroviral</Keyword>\n        </KeywordList>\n    </MedlineCitation>\n    <PubmedData>\n        <History>\n            <PubMedPubDate PubStatus="received">\n                <Year>2017</Year>\n                <Month>02</Month>\n                <Day>21</Day>\n            </PubMedPubDate>\n            <PubMedPubDate PubStatus="revised">\n                <Year>2017</Year>\n                <Month>04</Month>\n                <Day>06</Day>\n            </PubMedPubDate>\n            <PubMedPubDate PubStatus="accepted">\n                <Year>2017</Year>\n                <Month>04</Month>\n                <Day>08</Day>\n            </PubMedPubDate>\n            <PubMedPubDate PubStatus="pubmed">\n                <Year>2017</Year>\n                <Month>6</Month>\n                <Day>6</Day>\n                <Hour>6</Hour>\n                <Minute>0</Minute>\n            </PubMedPubDate>\n            <PubMedPubDate PubStatus="medline">\n                <Year>2019</Year>\n                <Month>4</Month>\n                <Day>17</Day>\n                <Hour>6</Hour>\n                <Minute>0</Minute>\n            </PubMedPubDate>\n            <PubMedPubDate PubStatus="entrez">\n                <Year>2017</Year>\n                <Month>6</Month>\n                <Day>6</Day>\n                <Hour>6</Hour>\n                <Minute>0</Minute>\n            </PubMedPubDate>\n        </History>\n        <PublicationStatus>ppublish</PublicationStatus>\n        <ArticleIdList>\n            <ArticleId IdType="pubmed">28579016</ArticleId>\n            <ArticleId IdType="pii">S0213-005X(17)30131-3</ArticleId>\n            <ArticleId IdType="doi">10.1016/j.eimc.2017.04.001</ArticleId>\n        </ArticleIdList>\n    </PubmedData>\n</PubmedArticle>\n\n</PubmedArticleSet>'